In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received ...

Editor's note: This story has been revised to include additional comments. CHICAGO — In patients with stage IVB anaplastic ...

Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Cue Biopharma (CUE – Research Report), with a ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the results from the phase 3 KEYNOTE-522 trial.

Data suggest that cabozantinib and pembrolizumab can be effective in patients with advanced gastric or gastroesophageal junction cancer whose disease is resistant or refractory to immune checkpoint ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

MONDAY, Oct. 21, 2024 (HealthDay News) -- Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...